Specificity: reacts to Human Integrin beta3A/CD61.
Recombinant rabbit monoclonal antibodies are produced using in vitro expression systems. The expression systems are developed by cloning in the specific antibody DNA sequences from immunoreactive rabbits. Then, individual clones are screened to select the best candidates for production. The advantages of using recombinant rabbit monoclonal antibodies include: better specificity and sensitivity, lot-to-lot consistency, animal origin-free formulations, and broader immunoreactivity to diverse targets due to larger rabbit immune repertoire.
ITGB3 is involved in Glanzmann thrombasthenia (GT), a common inherited disease of platelet aggregation. It is characterized by mucocutaneous bleeding of mild-to-moderate severity. GT has been classified clinically into types I and II. In type I, platelets show absence of the glycoprotein IIb-IIIa complexes at their surface and lack fibrinogen and clot retraction capability. In type II, the platelets express the GPIIb-IIIa complex at reduced levels, have detectable amounts of fibrinogen, and have low or moderate clot retraction capability. The disease is caused by mutations affecting the gene represented in this entry.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Protein Aliases: antigen CD61; CD61; GPIIIa; integrin beta 3; Integrin beta-3; integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61); Platelet membrane glycoprotein IIIa
Gene Aliases: BDPLT16; BDPLT2; CD61; GP3A; GPIIIa; GT; ITGB3
UniProt ID: (Human) P05106
Entrez Gene ID: (Human) 3690